Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; Diabetes TrialNet and the Immune Tolerance Network.

Diabetes. 2012 Sep;61(9):2340-8. doi: 10.2337/db12-0049. Epub 2012 Jun 20.

2.

Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists.

Cheng K, Kim IJ, Lee MJ, Adah SA, Raymond TJ, Bilsky EJ, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Rothman RB, Jacobson AE, Rice KC.

Org Biomol Chem. 2007 Apr 21;5(8):1177-1190. doi: 10.1039/b618875c. Epub 2007 Mar 1.

PMID:
17406716
3.

Chemistry and biochemistry of 2',5'-oligoadenylate-based antisense strategy.

Adah SA, Bayly SF, Cramer H, Silverman RH, Torrence PF.

Curr Med Chem. 2001 Aug;8(10):1189-212.

PMID:
11472236
4.

2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection.

Barnard DL, Sidwell RW, Xiao W, Player MR, Adah SA, Torrence PF.

Antiviral Res. 1999 Apr;41(3):119-34.

PMID:
10320045

Supplemental Content

Support Center